Esperion Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview

Esperion Therapeutics

09/08/2024 19:36

* Esperion Therapeutics Inc  ESPR.OQ   ESPR.O  is expected
to show
a rise in quarterly revenue when it reports  results on August
12 for the period ending June 30 2024
    * The Vero Beach Florida-based  company is expected to
report a
90.2% increase in revenue to $49.056 million from $25.79 million
a year ago, according to the mean estimate from 8 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Esperion Therapeutics
Inc is
for a loss of 17 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Esperion
Therapeutics Inc is $8.00​, above​ its last closing price
of $2.03. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  0.08        0.05       0.34      Beat    627.3
 Dec. 31 2024  -0.41       -0.48      -0.50     Missed  -3.6
 Sep. 30 2023  -0.43       -0.43      -0.37     Beat    14.4​
 Jun. 30 2023  -0.62       -0.61      -0.46     Beat    24.8
 ​​Mar.        -0.64       -0.65      -0.79     Missed  -21.1
 31 2023                                                
 Dec. 31 2022  -0.82       -0.84      -0.76     Beat    9.6​
 Sep. 30 2022  -0.92       -0.92      -0.81     Beat    12.4
 Jun. 30 2022  -0.92       -0.93      -1.05     Missed  -13.4
 This summary was machine generated August 9 at 18:35 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)